Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma

被引：1

作者：

Lapuente, Maria ^{[1
]}

Conway, Dawn ^{[2
]}

Wood, Laura S. ^{[3
]}

Kehoe, Kiran ^{[4
]}

Bullock, Andrea Carroll ^{[5
]}

Devgan, Geeta ^{[6
]}

Burns, Kathleen D. ^{[7
]}

机构：

[1] Bartholomews Hosp, London, England

[2] Univ Chicago Med Illinois, Genitourinary Oncol, Chicago, IL USA

[3] Cleveland Clin Ohio, Taussig Canc Ctr, Cleveland, OH USA

[4] Mem Sloan Kettering Canc Ctr, New York, NY USA

[5] North Amer Med Commun EMD Serono, Rockland, MA, Brazil

[6] Pfizer, US Med Affairs, New York, NY USA

[7] City Hope Natl Med Ctr, Natl Canc Ctr, Duarte, CA USA

来源：

CLINICAL JOURNAL OF ONCOLOGY NURSING | 2023年 / 27卷 / 01期

关键词：

avelumab first-line maintenance; bladder cancer; immune-related adverse events; CHEMOTHERAPY; CANCER; CISPLATIN;

D O I：

10.1188/23.CJON.71-80

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND:The phase 3 of JAVELIN Bladder 100 trial demonstrated that avelumab first-line (1L) maintenance in addition to best supportive care significantly prolonged overall survival compared to best supportive care alone. It is now the standard of care for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma that has not progressed with 1L platinum-containing chemotherapy.OBJECTIVES: This article provides considerations for oncology nurses to effectively implement avelumab 1L maintenance treatment in the clinical setting.METHODS: This article reviews clinical evidence and implications for oncology nurses caring for patients receiving avelumab 1L maintenance treatment.FINDINGS: Oncology nurses can provide compre-hensive care for patients with advanced urothelial carcinoma and ensure the safe and appropriate use of avelumab 1L maintenance treatment by educating patients and caregivers, ensuring correct adminis-tration, and promptly recognizing and managing immune-related adverse events.

引用

页码：71 / 80

页数：10

共 50 条

[31] Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States
Moon, Helen H.
Kearney, Mairead
Mahmoudpour, Seyed Hamidreza
Ike, Chiemeka
Morris, Valerie
Rava, Andrew
Kim, Sonia
Sun, Haiyan
Boyd, Marley
Gomez Rey, Gabriel
CURRENT ONCOLOGY, 2024, 31 (09) : 5662 - 5676
[32] Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program
Park, Se Hoon
Shin, Sang Joon
Rha, Sun Young
Beom, Seung-Hoon
Seo, Ho Kyung
Keam, Bhumsuk
Kim, Miso
Hong, Yoon-Hee
Yoon, Shinkyo
Lee, Jae-Lyun
FRONTIERS IN ONCOLOGY, 2024, 14
[33] J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan
Kikuchi, Eiji
Hayakawa, Nozomi
Nakayama, Masashi
Uno, Masahiro
Nakatsu, Hiroomi
Kitagawa, Chiyoe
Miyake, Hideaki
Yamada, Takeshi
Fujita, Kazutoshi
Shimoyama, Hideaki
Nishihara, Kiyoaki
Kobayashi, Mizuki
Nakamura, Motonobu
Fujimoto, Kiyohide
Sano, Takeshi
Nishiyama, Naotaka
Ito, Takayuki
Kajita, Masahiro
Kobayashi, Takashi
Kitamura, Hiroshi
INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (08) : 859 - 867
[34] Avelumab Maintenance Therapy in Advanced Urothelial Carcinoma: Implications of Timing and Treatment Sequencing
Goncalves, Lisa
Guedes, Helena
Fortuna, Ana Raquel
Lemos, Tania
Gramaca, Joao
Mourao, Natacha
Cunha, Goncalo
Pichel, Rita
Simoes, Pedro
Luis, Joana Alves
Freitas, Rita
Dunoes, Ines
Spencer, Ana Sofia
Marinho, Joana
Costa, Luis
CANCERS, 2025, 17 (05)
[35] Vinflunine maintenance treatment following first-line therapy of advanced urothelial carcinoma - results from the JASiMA trial
De Wit, M.
De Geeter, P.
Galli, L.
Hegele, A.
Schrader, M.
Schenck, M.
Dorp, F. Vom
Bolten, M.
Fahlenkamp, D.
Hampel, C.
Krause, S.
Riggi, M.
Fougeray, R.
De Almeida, C.
Edlich, B.
Pichler, A.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S527 - S527
[36] Avelumab first-line maintenance for advanced urothelial carcinoma: analysis of clinical and genomic subgroups from the phase 3 JAVELIN Bladder 100 trial
Lumba, Sumit
Powles, Thomas
Petrylak, Daniel P.
Park, Se Hoon
Sridhar, Srikala S.
Caserta, Claudia
Thiery-Vuillemin, Antoine
Lee, Hyo Jin
Bellmunt, Joaquim
Yamamoto, Yoshiaki
Aragon-Ching, Jeanny B.
Huang, Bo
Ching, Keith A.
Davis, Craig
di Pietro, Alessandra
Loriot, Yohann
Grivas, Petros
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 44 - 45
[37] Avelumab first-line maintenance for advanced urothelial carcinoma: analysis of clinical and genomic subgroups from the phase 3 JAVELIN Bladder 100 trial
Lumba, Sumit
Powles, Thomas
Petrylak, Daniel P.
Park, Se Hoon
Sridhar, Srikala S.
Caserta, Claudia
Thiery-Vuillemin, Antoine
Lee, Hyo Jin
Bellmunt, Joaquim
Yamamoto, Yoshiaki
Aragon-Ching, Jeanny B.
Huang, Bo
Ching, Keith A.
Davis, Craig
di Pietro, Alessandra
Loriot, Yohann
Grivas, Petros
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 126 - 127
[38] Avelumab first-line maintenance therapy for locally advanced/metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study.
Grivas, Petros
Barata, Pedro C.
Moon, Helen H.
Gupta, Shilpa
Hutson, Thomas E.
Sternberg, Cora N.
Brown, Jason
Dave, Vaidehi
Downey, Chad
Shillington, Alicia C.
Katzenstein, Howard
Kirker, Melissa
Hanson, Sarah
Liu, Frank X.
Morris, Valerie A.
Bhanegaonkar, Abhijeet
Sonpavde, Guru P.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 697 - 697
[39] Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma
Hoffman-Censits, Jean
Wong, Yu-Ning
CLINICAL GENITOURINARY CANCER, 2015, 13 (04) : 302 - 308
[40] Avelumab Maintenance for Urothelial Carcinoma
Buti, Sebastiano
Bersanelli, Melissa
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25): : 2482 - 2483

← 1 2 3 4 5 →